Compass Therapeutics, Inc.CMPXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank53
3Y CAGR+67.8%
5Y CAGR-19.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+67.8%/yr
vs -46.9%/yr prior
5Y CAGR
-19.9%/yr
Recent acceleration
Acceleration
+114.7pp
Accelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 6.61% |
| Q3 2025 | -21.86% |
| Q2 2025 | 25.75% |
| Q1 2025 | 0.12% |
| Q4 2024 | 51.39% |
| Q3 2024 | -22.93% |
| Q2 2024 | 17.35% |
| Q1 2024 | -23.37% |
| Q4 2023 | 40.71% |
| Q3 2023 | -13.62% |
| Q2 2023 | 54.01% |
| Q1 2023 | -33.14% |
| Q4 2022 | 1.40% |
| Q3 2022 | 67.02% |
| Q2 2022 | 32.77% |
| Q1 2022 | -53.89% |
| Q4 2021 | 203.55% |
| Q3 2021 | 8.57% |
| Q2 2021 | -38.24% |
| Q1 2021 | 6.76% |
| Q4 2020 | 20.05% |
| Q3 2020 | 22.95% |
| Q2 2020 | -16.41% |
| Q1 2020 | 8.11% |
| Q4 2019 | -44.76% |
| Q3 2019 | 10.95% |
| Q2 2019 | -25.60% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |